RESEARCH ARTICLE

Maternal white blood cell count cannot identify the presence of microbial invasion of the amniotic cavity or intra-amniotic inflammation in women with preterm prelabor rupture of membranes

Ivana Musilova¹, Lenka Pliskova², Romana Gerychova³, Petr Janku³, Ondrej Simetka⁴, Petr Matlak⁴, Bo Jacobsson⁵,⁶, Marian Kacerovsky¹,⁷*

¹ Department of Obstetrics and Gynecology, Charles University Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, ² Institute of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, ³ Department of Obstetrics and Gynecology, University Hospital Brno, Faculty of Medicine Masaryk University, Brno, Czech Republic, ⁴ Department of Gynecology and Obstetrics, University Hospital Ostrava, Ostrava, Czech Republic, ⁵ Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁶ Domain of Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway, ⁷ Biomedical Research Center, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

* kacermar@fnhk.cz

Abstract

Objective

The main aim of this study was to determine the relationship between the maternal white blood cell count (WBC) at the time of hospital admission in pregnancies complicated by preterm prelabor rupture of membranes (PPROM) and the presence of microbial invasion of the amniotic cavity (MIAC) and/or intra-amniotic inflammation (IAI). The second aim was to test WBC diagnostic indices with respect to the presence of MIAC and/or IAI.

Methods

Four hundred and seventy-nine women with singleton pregnancies complicated by PPROM, between February 2012 and June 2017, were included in this study. Maternal blood and amniotic fluid samples were collected at the time of admission. Maternal WBC count was assessed. Amniotic fluid interleukin-6 (IL-6) concentration was measured using a point-of-care test, and IAI was characterized by an IL-6 concentration of ≥ 745 pg/mL. MIAC was diagnosed based on a positive polymerase chain reaction result for the Ureaplasma species, Mycoplasma hominis, and/or Chlamydia trachomatis and/or for the 16S rRNA gene.

Results

Women with MIAC or IAI had higher WBC counts than those without (with MIAC: median, 12.8 × 10⁹/L vs. without MIAC: median, 11.9 × 10⁹/L; p = 0.0006; with IAI: median, 13.7 × 10⁹/L vs.
without IAI: median, $11.9 \times 10^9/L; p < 0.0001$). When the women were divided into four sub-
groups based on the presence of MIAC and/or IAI, the women with both MIAC and IAI had a
higher WBC count than those with either IAI or MIAC alone, and those without MIAC and IAI
[between MIAC and IAI: median, $14.0 \times 10^9/L$; IAI alone: $12.1 \times 10^9/L (p = 0.03)$; MIAC alone: $12.1$
$\times 10^9/L (p = 0.0001)$; and without MIAC and IAI: median, $11.8 \times 10^9/L (p < 0.0001)$]. No differ-
ences in the WBC counts were found among the women with IAI alone, MIAC alone, and with-
out MIAC and IAI.

**Conclusion**

The women with both MIAC and IAI had a higher maternal WBC count at the time of hospital
admission than the remaining women with PPROM. The maternal WBC count at the time of
admission showed poor diagnostic indices for the identification of the presence of both
MIAC and IAI. Maternal WBC count at the time of admission cannot serve as a non-invasive
screening tool for identifying these complications in women with PPROM.

**Introduction**

Preterm prelabor rupture of membranes (PPROM), characterized by the rupture of the fetal
membranes, with leakage of amniotic fluid, before spontaneous onset of regular uterine con-
tractions prior to 37 weeks of gestation, has been considered a difficult, serious, and controver-
sial perinatal complication since many years [1, 2]. Characterization of PPROM pregnancies
differs based on their causality and pathophysiology: i) infection and inflammation in the
choriodecidual space and amniotic cavity; ii) bleeding associated with placental abruption; and
iii) non-infectious premature aging of the fetal membranes [1–6]. Regardless of the PPROM
etiology and pathophysiology, PPROM might jeopardize the fetus by premature birth and its
consequences [7]. In addition, PPROM might threaten both the fetus and the mother because
of the presence of microbial invasion of the amniotic cavity (MIAC) and intra-amniotic
inflammation (IAI), which may lead to the development of histological and even clinical chor-
ioamnionitis [8–10].

At this stage, evaluation of amniotic fluid samples alone, obtained via transabdominal
amniocentesis, might present precise information on the intra-amniotic environment. The
feasibility of transabdominal amniocentesis in PPROM dramatically changes over time (the
success rate has increased from 49% to 96%), mainly owing to the progress in ultrasound
technology [11, 12]. In addition, this procedure can be considered safe for both mothers and
fetuses [12]. Nonetheless, the majority of obstetricians are reluctant to perform amniocentesis
in women with PPROM owing to its invasiveness and the relative technical difficulty associ-
ated with the scenario, which involves a very low volume of residual amniotic fluid. Therefore,
non-invasive markers for the identification of intra-amniotic complications associated with
PPROM are still needed.

Various markers from non-invasively obtained body fluids have been suggested over the
decades; however, the evaluation of maternal white blood cell (WBC) count in the 1990s
could be considered an important pioneering step in the process of a non-invasive biomarker-
seeking process [11, 13–15]. Currently, the WBC count has not been taken into consideration
as a very useful marker for infection-related and inflammatory intra-amniotic PPROM com-
plications for at least two reasons: i) a wide range of normal maternal WBC count during
pregnancy [16] and ii) the studies with the presence of acute histological chorioamnionitis, clinical chorioamnionitis, and neonatal infection as the outcomes have reported that maternal WBC counts were poor diagnostic indices for these outcomes [10, 11, 13–15, 17–24]. Despite these data, the evaluation of maternal WBC count is still a part of the clinical protocol in women with PPROM in a number of countries worldwide.

Since women with PPROM prior to the 34th completed gestational week are typically treated expectantly, the latency (the interval between rupture of the membranes and delivery) might be long. Therefore, the presence of histological chorioamnionitis and the development of neonatal infection as outcomes, cannot appropriately describe the actual intra-amniotic environment at the time of admission to hospital of women with PPROM. For this reason, MIAC and IAI appear to be ideal outcomes, since the sampling of both the maternal and intra-amniotic environment might be performed at the same time. Nevertheless, there is a paucity of information to whether and how the presence of MIAC and/or IAI affects the maternal WBC count at the time of admission of women with PPROM.

Therefore, the main aim of this study was to determine the relationship between maternal WBC counts on admission to hospital and the presence of MIAC and IAI in women with PPROM. The second aim of this study was to assess the association between the maternal WBC count and amniotic fluid interleukin (IL)-6 concentrations at the time of admission. The final aim was to characterize the maternal WBC count at the time of admission in four subgroups of women with PPROM subdivided on the basis of the presence and/or absence of MIAC and/or IAI.

Materials and methods

This prospective cohort study was conducted between February 2012 and June 2017. Women admitted to the Department of Obstetrics and Gynecology, University Hospital in Hradec Kralove, Czech Republic, were recruited if they had pregnancies complicated by PPROM between gestational ages 24+0 and 36+6 weeks. Only women aged at least 18 years with a singleton pregnancy were eligible for the study. Women with any medical complications (e.g., hypertension, preeclampsia, diabetes mellitus, and thyroid disease), fetal growth restriction, gross vaginal bleeding, signs of fetal hypoxia, and structural malformations or chromosomal abnormalities of the fetus were excluded from the study. Gestational age was established for all pregnancies based on the first trimester ultrasound results.

PPROM was defined as the leakage of amniotic fluid prior to the onset of labor and was diagnosed visually via a sterile speculum examination to confirm the pooling of amniotic fluid in the vagina. In case of clinical doubt, PPROM was confirmed by the presence of insulin-like growth factor-binding protein (ACTIM PROM test; MediX Biochemica, Kauniainen, Finland) in the vaginal fluid.

Women with PPROM at less than 34 weeks of gestation were treated using tocolytics for 48 hours, antibiotics, and corticosteroids to accelerate lung maturation. Those with PPROM beyond 34 weeks of gestation were treated only with antibiotics. The women with PPROM included in this study were managed with two different approaches. Between February 2012 and December 2013, transabdominal amniocenteses were performed only for research purposes, and the results from amniotic fluid analyses were not used for clinical management. During this period women with PPROM were treated actively (except those at < 28 gestational weeks). Labor was induced, or an elective cesarean section was performed no later than 72 hours after the rupture of the membranes, depending on the gestational age of the pregnancy, fetal status, and maternal serum C-reactive protein concentrations. Since January 2014, the performance of transabdominal amniocentesis procedures and collection of information on
the presence of MIAC and/or IAI have become a routine part of the clinical management of women with PPROM at our department. Thus, women with PPROM admitted between January 2014 and July 2017 were managed differently. Women with both MIAC and IAI beyond the 28th gestational week were managed actively (labor was induced, or an elective cesarean section was performed after finalizing corticosteroid treatment within 72 hours of membrane rupture for pregnancies before 34 weeks of gestational age and within 24 hours of membrane rupture for those beyond 34 weeks). The remaining women with PPROM were managed expectantly. Since maternal and intra-amniotic samples were obtained simultaneously during the hospital admission, the differences in management protocols over the study period could not affect the results of this study.

This study’s protocol was approved by the Ethics Committee of the University Hospital of Hradec Kralove, Czech Republic (March 19, 2008; No. 200804 SO1P, which was renewed in July 2014; decision No. 201407 S14P), and written informed consent was obtained from all the participants.

Amniotic, cervical, crevicular, and vaginal fluid samples from this cohort of women have been used in our previously published studies [8, 25–45]. One hundred and ninety-two and 287 women from this study have taken part in our previous studies on the associations between maternal serum C-reactive protein concentrations and MIAC and/or histological chorioamnionitis and MIAC and/or IAI, respectively [37, 45].

Maternal blood and amniotic fluid sampling
For all women, the maternal blood and amniotic fluid samples were collected at the time of hospital admission (maternal blood first, followed by amniotic fluid) prior to the administration of corticosteroids, antibiotics, or tocolytics. Maternal blood samples were obtained via venipuncture of the cubital vein and were sent to the laboratory for the assessment of the WBC count immediately following sampling. Ultrasound-guided transabdominal amniocentesis was performed, and ~5 mL of amniotic fluid was aspirated. A total of 100 μL of non-centrifuged amniotic fluid was used for the bedside assessment of interleukin (IL)-6 concentrations, and one tube with non-centrifuged amniotic fluid was transported to the laboratory for DNA isolation, detection of the Ureaplasma species, Mycoplasma hominis (M. hominis), and Chlamydia trachomatis (C. trachomatis) using polymerase chain reaction (PCR), and 16S rRNA gene sequencing.

Amniotic fluid IL-6 concentrations
The amniotic fluid IL-6 concentrations were assessed using the Milenia QuickLine IL-6 lateral flow immunoassay on the Milenia® POC Scan Reader (Milenia Biotec, GmbH, Giessen, Germany). The measurement range was 50–10,000 pg/mL. The intra-assay and inter-assay coefficients of variation were 12.1% and 15.5%, respectively [26].

Detection of the Ureaplasma species, M. hominis, and C. trachomatis
DNA was isolated from the amniotic fluid using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions (using the protocol for isolation of bacterial DNA from biological fluids). Real-time PCR was conducted on a Rotor-Gene 6000 instrument (Qiagen) using the commercial kit AmpliSens® C. trachomatis/Ureaplasma/M. hominis-FRT (Federal State Institution of Science, Central Research Institute of Epidemiology, Moscow, Russia) to detect the DNA of the Ureaplasma species, M. hominis, and C. trachomatis using the same PCR tube. As a control, we included a PCR for β-actin, a housekeeping gene, to examine for the presence of PCR inhibitors [46]. The amount of target DNA in the sample was measured based on the threshold cycle (Ct) value [47]. The Ct value is the intersection between
an amplification curve and a threshold line. It is a measurement method used to determine the concentration of the target DNA in the PCR. Under ideal conditions, the amount of target amplicon increases at a rate of one \( \log_{10} \) every 3.32 cycles, which means that decreasing the microbial load of the \textit{Ureaplasma} species in the amniotic fluid results in higher Ct values [47].

Detection of other bacteria in the amniotic fluid

Bacterial DNA was identified by PCR targeting the 16S rRNA gene using the following primers: 5’-CCAGACTCTATACGGAGGCA-3’ (V3 region) and 5’-ACATTCTCAACACGAGCTGAGCA-3’ (V6 region) [48, 49]. The PCR products from 16S rRNA were purified and used in sequencing the PCR reactions with the abovementioned primers and the BigDye Terminator kit, v3.1 (Thermo Fisher Scientific, Waltham, MA, USA). The bacteria were then typed using the sequences obtained in the BLAST\textsuperscript{1} and SepsiTest\textsuperscript{™} BLAST databases.

Diagnosis of MIAC

MIAC was diagnosed using a non-culture-based approach. MIAC was defined as a positive PCR result for the \textit{Ureaplasma} species, \textit{M. hominis}, and/or \textit{C. trachomatis} or positivity of the 16S rRNA gene in the amniotic fluid.

Diagnosis of IAI

IAI in pregnancies with PPROM was defined as bedside amniotic fluid IL-6 concentrations of \( \geq 745 \) pg/mL [50, 51].

Statistical analyses

The demographic and clinical characteristics of women were compared using the nonparametric Kruskal-Wallis test for continuous variables and were presented as median values (ranges). Categorical variables were compared using the chi-square test and were presented as numbers (%). The maternal WBC counts were compared using either the Mann-Whitney \( U \) test or Kruskal-Wallis test with post hoc Dunn’s analysis, as appropriate, and presented as median values [interquartile ranges (IQRs)]. Spearman’s partial correlation was used to adjust the significance of the results for potential confounders (gestational age at sampling, parity, latency from PPROM to amniocentesis, and smoking history). To identify an association between maternal WBC count and microbial loads of the \textit{Ureaplasma} species and amniotic fluid IL-6 concentrations, Spearman’s correlations were used. Differences were considered significant at \( p < 0.05 \). All \( p \)-values were obtained in two-sided tests, and all statistical analyses were performed using the GraphPad Prism version 6.0 software for Mac OS X (GraphPad Software, San Diego, CA, USA) or the SPSS version 19.0 statistical package for Mac OS X (SPSS Inc., Chicago, IL, USA).

Results

Demographic and clinical characteristics of the study population

A total of 526 women with singleton pregnancy complicated by PPROM were admitted during the study period, although only 479 women were included in the analyses. The flow diagram describing the selection of women is shown in Fig 1.

The presence of MIAC and IAI was identified in 27% (130/479) and 21% (99/479) of the women, respectively. When the women were divided into four subgroups based on the presence and absence of MIAC and IAI, the presence of both MIAC and IAI was found in 14% (68/479); the presence of IAI alone in 7% (31/479); the presence of MIAC alone in 13% (62/479); and the presence of neither MIAC nor IAI was found in 66% (318/479) of the women.
The demographic and clinical characteristics of the women with PPROM with respect to the presence of MIAC and/or IAI are shown in Table 1. The most common bacteria found in the amniotic fluid were the *Ureaplasma* species, which were identified in 19% (89/479) of the women. Polymicrobial findings in the amniotic fluid were observed in 4% (19/479) of the women. All microbial findings are shown in Table 2.

Women with PPROM included in this study were treated with two different management strategies (an active management between January 2012 and December 2013 and an individualized management based on the presence of both MIAC and IAI between January 2014 and December 2017). The active management was associated with a lower gestational age at delivery (medians: 33+4 weeks vs. 34+2 weeks; \( p = 0.002 \)), birth weight (medians: 2020 g vs. 2240 g; \( p = 0.01 \)), a shorter latency (medians: 40 hours vs. 48 hours; \( p = 0.04 \)), and a higher rate of cesarean section (60% vs. 35%; \( p = 0.004 \)). All the women were self-reported Caucasians.

Maternal WBC counts based on the presence of MIAC

The women with MIAC had higher WBC counts than the women without MIAC (with MIAC: median, \( 12.8 \times 10^9 /L \), IQR: 10.8–15.8 \( \times 10^9 \) vs. without MIAC: median, \( 11.9 \times 10^9 /L \), IQR: 9.8–14.4 \( \times 10^9 \); \( p = 0.0006 \); Fig 2a) in the crude analysis, as well as after adjustments for gestational age at sampling, smoking, parity, and interval from PPROM to amniocentesis (\( p = 0.02 \)). No differences in the maternal WBC count between the women with genital mycoplasmas (*Ureaplasma* species and/or *M. hominis*) and women with the other bacteria in the amniotic fluid...
were found (with genital mycoplasmas: median, 12.7 \times 10^9/L, IQR: 10.5–15.8 \times 10^9 vs. with the other bacteria: median, 13.1 \times 10^9/L, IQR: 11.2–15.8 \times 10^9; \ p = 0.59). A weak correlation between the microbial burden of the *Ureaplasma* species (characterized by Ct values) in the amniotic fluid and maternal WBC count was identified (rho = -0.33, \ p = 0.002).

Maternal WBC counts based on the presence of IAI

Women with IAI had higher WBC counts than the women without IAI (with IAI: median, 13.7 \times 10^9/L, IQR: 11.2–16.7 \times 10^9 vs. without IAI: median, 11.9 \times 10^9/L, IQR: 9.8–13.9 \times 10^9; \ p < 0.0001; Fig 2b) in the crude analysis and in the adjusted analysis for gestational age at sampling, smoking history, parity, and interval from PPROM to amniocentesis (\ p < 0.0001). A weak correlation between the maternal WBC count and amniotic fluid IL-6 concentrations was found (rho = 0.24; \ p < 0.0001).

Maternal WBC counts based on the presence of MIAC and/or IAI

When the women were divided into four subgroups according to the presence of MIAC and/or IAI, differences in WBC counts on admission were identified (women with both MIAC

Table 1. Demographic and clinical characteristics of women with PPROM stratified according to the presence and absence of MIAC and/or IAI.

| Characteristic                                      | With MIAC and IAI (n = 68) | With IAI alone (n = 31) | With MIAC alone (n = 62) | Without MIAC and IAI (n = 318) | \(p\) value |
|----------------------------------------------------|---------------------------|------------------------|-------------------------|--------------------------------|-------------|
| Maternal age [years, median (range)]               | 31 (17–42)                | 30 (21–38)             | 31 (18–42)              | 31 (18–43)                     | 0.90        |
| Primiparous [number (%)]                           | 25 (37%)                  | 17 (55%)               | 27 (44%)                | 169 (53%)                      | 0.06        |
| Pre-pregnancy body mass index [kg/m\(^2\), median (range)] | 22.5 (17.4–38.2)          | 24.2 (18.3–38.6)       | 22.1 (16.0–35.1)        | 22.7 (16.4–57.4)               | 0.09        |
| Smoking history [number (%)]                       | 25 (37%)                  | 3 (10%)                | 11 (18%)                | 31 (10%)                       | 0.0001      |
| Gestational age at admission [weeks, median (range)] | 31+3 (24+0–36+6)          | 31+3 (24+0–36+6)       | 34+3 (25+3–36+6)        | 34+0 (24+0–36+6)               | < 0.0001    |
| Gestational age at delivery [weeks, median (range)] | 31+4 (24+0–36+6)          | 32+5 (25+0–37+0)       | 34+6 (26+6–37+0)        | 34+2 (24+0–36+6)               | < 0.0001    |
| Interval from PPROM to amniocentesis [hours, median (range)] | 7 (1–575)                 | 4 (2–432)              | 4 (1–206)               | 5 (1–600)                      | 0.06        |
| Latency from amniocentesis to delivery [hours, median (range)] | 45 (3–624)               | 71 (4–1392)            | 37 (4–390)              | 39 (2–768)                     | 0.05        |
| Amniotic fluid IL-6 concentration [pg/mL, median (range)] | 10000 (747–10000)        | 1363 (751–10000)       | 186 (50–673)            | 183 (50–729)                   | < 0.0001    |
| CRP concentration at admission [mg/L, median (range)] | 12.6 (0–113.0)           | 6.3 (1.0–59.3)         | 4.3 (0–28.9)            | 4.9 (0–47.5)                   | < 0.0001    |
| Administration of antibiotics [number (%)]         | 67 (99%)                  | 30 (97%)               | 62 (100%)               | 313 (98%)                      | 0.66        |
| Administration of corticosteroids [number (%)]     | 54 (79%)                  | 21 (68%)               | 37 (60%)                | 198 (62%)                      | 0.03        |
| Spontaneous vaginal delivery [number (%)]          | 44 (65%)                  | 21 (68%)               | 50 (81%)                | 216 (68%)                      | 0.19        |
| Cesarean delivery [number (%)]                     | 24 (35%)                  | 10 (32%)               | 11 (18%)                | 98 (31%)                       | 0.14        |
| Forceps delivery [number (%)]                      | 0 (0%)                    | 0 (0%)                 | 1 (2%)                  | 4 (1%)                         | 0.71        |
| Birth weight [grams, median (range)]               | 1620 (650–3540)           | 1945 (660–3320)        | 2300 (780–3250)         | 2245 (680–3670)                | < 0.0001    |
| Apgar score < 7; 5 minutes [number (%)]            | 4 (6%)                    | 2 (6%)                 | 0 (0%)                  | 8 (3%)                         | 0.14        |
| Apgar score < 7; 10 minutes [number (%)]           | 1 (2%)                    | 1 (3%)                 | 0 (0%)                  | 4 (1%)                         | 0.62        |

Abbreviations: PPROM: preterm prelabor rupture of membranes; MIAC: microbial invasion of the amniotic cavity; IAI: intra-amniotic inflammation; IL: interleukin; CRP: C-reactive protein

Continuous variables are compared using the nonparametric Kruskal-Wallis test. Categorical variables are compared using the chi-square test. Statistically significant results are marked in bold. Continuous variables are presented as medians (ranges) and categorical variables as numbers (%).
and IAI: median, 14.0 × 10⁹/L, IQR: 11.9–17.0 × 10⁹; women with IAI alone: median, 12.1 × 10⁹/L, IQR: 9.7–15.3 × 10⁹; women with MIAC alone: median, 12.1 × 10⁹/L, IQR: 9.6–13.9 × 10⁹; and women without both MIAC and IAI: median, 11.8 × 10⁹/L, IQR: 9.8–13.9 × 10⁹; p < 0.0001; Fig 3) in the crude analysis, as well as after adjustments for gestational age at sampling, smoking history, parity, and interval from PPROM to amniocentesis (p < 0.0001). The women with both MIAC and IAI had higher WBC counts than the women with IAI alone (p = 0.03), women with MIAC alone (p = 0.0001), and women without MIAC and IAI (p < 0.0001). No differences in the WBC counts were identified among the women with IAI alone or MIAC alone and without both MIAC and IAI (IAI alone vs. MIAC alone: p = 0.36; IAI alone vs. without both MIAC and IAI: p = 0.26; and MIAC alone vs. without both MIAC and IAI: p = 0.87).

The WBC count cutoff value of 14.0 × 10⁹/L was found to be the most effective in identifying both MIAC and IAI, with a sensitivity of 50% [34/68; 95% confidence interval (CI), 38–62%], specificity of 75% (306/411; 95% CI, 70–78%), positive predictive value of 25% (34/139; 95% CI, 18–32%), negative predictive value of 90% (306/340; 95% CI, 86–93%), positive likelihood ratio of 2.0 (95% CI, 1.5–2.6), negative likelihood ratio of 0.7 (95% CI, 0.5–0.9), and area under the receiver-operating characteristic curve of 0.70 (95% CI, 0.63–0.76; p < 0.0001; Fig 4).

Table 2. The bacterial species identified in the amniotic fluid of women with PPROM.

| Women with MIAC and IAI (n = 68) | Women with MIAC alone (n = 62) |
|---------------------------------|-------------------------------|
| Ureaplasma species (33)        | Ureaplasma species (37)      |
| Ureaplasma species + Mycoplasma hominis (6) | Ureaplasma species + Chlamydia trachomatis (5) |
| Ureaplasma species + Chlamydia trachomatis (3) | Ureaplasma species + Leptotrichia amnionii (1) |
| Ureaplasma species + Lactobacillus species (1) | Mycoplasma hominis (6) |
| Ureaplasma species + Sneathia sanguinegens (1) | Chlamydia trachomatis (2) |
| Ureaplasma species + Enterococcus faecium (1) | Bifidobacterium species (1) |
| Chlamydia trachomatis (1)      | Gardnerella vaginalis (1) |
| Chlamydia trachomatis + Leptotrichia amnionii (1) | Lactobacillus gasseri (2) |
| Haemophilus influenza (3)      | Propionibacterium acnes (2) |
| Fusobacterium nucleatum (2)    | Staphylococcus haemolyticus (1) |
| Leptotrichia amnionii (1)      | Staphylococcus warneri (1) |
| Parvimonas micra 1x            | Streptococcus intermedius 1x |
| Peptococcus species 1x         | Streptococcus pneumoniae 1x |
| Peptoniphilus species 1x       | Streptococcus salivarius 1x |
| Propionibacterium acnes 1x     | Propionibacterium species 1x |
| Propionibacterium species 1x   | Sneathia sanguinegens 1x |
| Staphylococcus hominis 1x      | Streptococcus agalactiae 3x |
| Streptococcus condemmatus 1x   | Streptococcus intermedius 1x |
| Streptococcus species 1x       | Streptococcus salivarius 1x |
| Bacteria non-identifiable by sequencing 2x | |

Abbreviations:
PPROM: preterm prelabor rupture of membranes; MIAC: microbial invasion of the amniotic cavity; IAI: intra-amniotic inflammation

https://doi.org/10.1371/journal.pone.0189394.t002
Discussion

The assessment of WBC counts from blood samples is one of the most common approaches in evaluating the systemic inflammatory response and its intensity in non-pregnant women. During pregnancy, the maternal WBC count assessment has limited value owing to a broader range of reference values present across the trimesters than during non-pregnancy periods [16]. Nevertheless, there is still a gap in the knowledge with regard to whether and how the presence of MIAC and/or IAI affects the maternal WBC count in PPROM.

In this study, we attempted to bridge this gap in knowledge by providing the following key findings: i) the presence of MIAC was associated with a higher maternal WBC count at the time of admission; ii) no differences in the maternal WBC count between the women with genital mycoplasmas and the other bacteria in the amniotic fluid was found; iii) the microbial load of the Ureaplasma species weakly correlated with the maternal WBC count; iv) the presence of IAI correlated with a higher maternal WBC count at the time of admission to hospital; v) the maternal WBC count weakly correlated with amniotic fluid IL-6 concentrations; vi) the women with both MIAC and IAI had a higher maternal WBC count at the time of admission than the women with MIAC alone, IAI alone, and neither MIAC nor IAI; and vii) the maternal WBC count obtained at the time of admission had poorer diagnostic indices for identifying the presence of both MIAC and IAI.
White blood cells count

$p < 0.0001$

$p = 0.0001$

$p = 0.03$

$p = 0.26$

$p = 0.36$

$14.0$

$12.4$

$12.1$

$11.8$

Women with both MIAC and IAI (n=68)

Women with IAI alone (n=31)

Women with MIAC alone (n=62)

Women without MIAC and IAI (n=318)

Fig 3. Maternal serum WBC counts in the PPROM pregnancies complicated by the presence of MIAC and/or IAI. The women with both MIAC and IAI have a higher WBC count than the women with IAI alone, MIAC alone, and neither MIAC nor IAI. Abbreviations: WBC, white blood cell count; PPROM, preterm prelabor rupture of membranes; MIAC, microbial invasion of the amniotic cavity; IAI, intra-amniotic inflammation.

https://doi.org/10.1371/journal.pone.0189394.g003
The presence of MIAC has been shown to complicate about one third of PPROM pregnancies and to be associated with higher intra-amniotic, maternal inflammatory responses at the time of admission, as well as the fetal inflammatory response at the time of delivery [8, 19, 34, 52, 53]. In 1996, Yoon et al. published their study conducted on 90 women with PPROM where they showed that women with MIAC had higher maternal WBC counts at the time of admission to hospital [19]. Our findings are in accordance with the results of their study. When taken together, we confirmed that the presence of MIAC is associated with a higher maternal inflammatory response at the time of admission, even when measured by the WBC count. However, the small differences in the medians of maternal WBC counts between women with and without MIAC prevent the WBC count from being a useful clinical marker in predicting MIAC.

MIAC is a very heterogeneous condition complicated by the invasion of different microbes in the amniotic fluid and by their different microbial loads. Genital mycoplasmas are the most common and account for up to 75% of all the microbial species identified in the amniotic fluid [34, 52, 54] from women with PPROM [34, 52, 54]. There are conflicting results regarding the intra-amniotic inflammatory response elicited by genital mycoplasmas [54–56]. To date, it is not completely clear whether there may be differences in intra-amniotic inflammatory responses elicited by genital mycoplasmas compared to those elicited by other bacteria [54–56]. Therefore, it would be of interest to better discriminate whether the presence of genital mycoplasmas in the amniotic fluid is associated with different maternal inflammatory

Fig 4. Maternal WBC counts stratified according to the presence or absence of both MIAC and IAI. A receiver-operating characteristic curve for the presence of both MIAC and IAI is shown (the area under the curve is 0.70 for the WBC cutoff value of >14.0 × 10^9/L; \( p < 0.0001 \)). Abbreviations: WBC, white blood cell count; MIAC, microbial invasion of the amniotic cavity; IAI, intra-amniotic inflammation.

https://doi.org/10.1371/journal.pone.0189394.g004
responses as measured by the maternal WBC count as compared with the presence of other bacteria. In this study, we found no difference. However, this finding is not in accordance with that of a previous study by Oh et al., where the authors found a higher maternal inflammatory response in the subgroup with genital mycoplasmas [54]. The possible explanation for these conflicting results might be due to the fact that the intra-amniotic and maternal inflammatory responses to genital mycoplasmas have been shown to be dependent on microbial load [47, 57, 58]. Accordingly, we found a correlation between the microbial load of the *Ureaplasma* species and maternal WBC count. This finding is in line with that of our previous study showing the correlation between the maternal serum C-reactive protein concentrations and the microbial loads of the *Ureaplasma* species [47].

A plethora of researchers have evaluated the association between maternal WBC count and histological chorioamnionitis [11, 13–15, 17–24, 59]. However, there is limited information regarding the relationship between maternal WBC count and IAI [60]. Ferrazzi et al. found in cohort of 23 women that those with IAI had a higher maternal WBC count than those without IAI [60]. This finding has been confirmed in our study performed on 479 women with PPROM. Moreover, we have shown that the maternal inflammatory response, characterized by the maternal WBC count, reflects the intensity of the IAI response as determined by the amniotic fluid IL-6 concentration. This finding is very important from a clinical standpoint, since it shows that even a subclinical inflammatory intra-amniotic complication might affect the systemic maternal compartment.

Recently, the subdivision of women with PPROM into four subgroups based on the presence and absence of MIAC and/or IAI has been proposed by Romero et al. [61]. This group subdivision enables a more precise characterization of the intra-amniotic environment at the time of amniotic fluid sampling. The subgroup of women with both MIAC and IAI (microbial-induced IAI) has been shown to have the most intensive intra-amniotic and cervical inflammatory responses [32, 34, 61]. In a recent study from our group, the maternal inflammatory response, determined by the maternal serum C-reactive protein concentration, has been found to be the strongest in the subgroup of women affected by both MIAC and IAI [45]. The observation from the current study conducted on an approximately two-fold larger cohort of women, is in line with this finding; women with both MIAC and IAI had a higher maternal WBC count than the women in the remaining subgroups. This finding is clinically relevant as it suggests that this subgroup of PPROM differs from the others. Therefore, this specific subgroup of PPROM should receive particular attention and be treated more cautiously.

There is a solid body of evidence indicating that smoking is associated with an elevated WBC count [62, 63]. Interestingly, we found the highest number of smokers in the subgroup of women with the highest maternal WBC count, i.e. in women with both MIAC and IAI. The same subgroup of women had the longest interval from PPROM to amniocentesis. This means that the intra-amniotic environment of this subgroup of women was exposed to the cervical and vaginal microbiota longer than the remaining women. This longer exposure might have contributed to the development of MIAC and IAI. Therefore, smoking and the interval from PPROM to amniocentesis should be considered as potential confounders and the results should be interpreted, accordingly.

Over the years, different maternal WBC count cutoff values have been proposed to predict MIAC, histological or clinical chorioamnionitis, and neonatal infection [11, 13–15, 17–24, 59]. Although maternal WBC count can easily be evaluated between the time of admission and delivery, there are differences among previous studies with regard to the temporal relationship between the maternal blood WBC count sampling and outcomes. Using the time of admission as a time-point for the sampling, the suggested WBC count cutoff values to predict MIAC and histological or clinical chorioamnionitis have ranged from 10 x 10⁹/L to 16 x 10⁹/L [11, 14, 19,
However, none of these values have good predictive indices. To test whether maternal WBC count obtained at the time of admission could be a potential predictor of PPROM complicated by both MIAC and IAI, we identified the maternal WBC count cutoff value 14.0 × 10^9/L as ideal. This cutoff value is almost in the middle of the aforementioned proposed WBC count range. This cutoff value showed a good negative predictive value, but its positive predictive value and likelihood ratio were poor, as such, the latter prevents this WBC count cutoff value from being used in the clinical setting.

A major strength of this study is the fact that it contains a relatively large cohort of women with a clearly defined, specific phenotype of spontaneous preterm delivery (PPROM). Second, a transabdominal amniocentesis was successfully performed to obtain a sample of amniotic fluid in 99% of the women admitted to hospital. Third, the maternal serum and amniotic fluid samples were obtained simultaneously at the time of admission. Therefore, the maternal systemic inflammatory response, measured by the maternal WBC count, could be used to indicate the actual status of the intra-amniotic compartment. Fourth, the microbial load of the amniotic fluid Ureaplasma species was assessed. Lastly, the results were adjusted for gestational age at sampling, parity, the interval from PPROM and amniocentesis, and smoking, since these variables might have been as potential confounding factors.

Several limitations of this study should also be mentioned. First, since the study focused only on the association between the single assessment of the maternal WBC count at admission and the current intra-amniotic status, it did not contain any information on the temporal trend of the maternal WBC count during the latency period, nor on the association between the maternal WBC count and histological chorioamnionitis. Second, the upper detection limit of amniotic fluid IL-6 assessment was 10,000 pg/mL. Since 39 out of 479 women reached this upper detection limit, this might have affected the results regarding the correlation between the maternal serum WBC count and amniotic fluid IL-6 concentrations. Next, an extensive non-culture approach (combination of specific PCR for the Ureaplasma species, M. hominis, and C. trachomatis and non-specific PCR for 16S rRNA gene) was used to evaluate MIAC in this study; however, underemphasizing of the MIAC negative group cannot be ruled out as the culture data is missing [52]. Lastly, the amniotic fluid WBC count was not evaluated, since this was not part of our clinical management of PPROM.

In conclusion, women with PPROM complicated by both MIAC and IAI had a higher maternal WBC count than the women without these conditions or than women exhibiting either MIAC or IAI alone. The maternal WBC count at the time of hospital admission showed poor diagnostic indices for the identification of the presence of both MIAC and IAI. Thus, the maternal WBC count cannot serve as a non-invasive screening tool in identifying these complications in women with PPROM.

**Supporting information**

S1 Dataset.

(XLS)

**Author Contributions**

**Conceptualization:** Ivana Musilova, Lenka Pliskova, Romana Gerychova, Petr Janku, Ondrej Simetka, Petr Matlak, Bo Jacobsson, Marian Kacerovsky.

**Data curation:** Marian Kacerovsky.

**Funding acquisition:** Marian Kacerovsky.
Methodology: Ivana Musilova, Lenka Pliskova, Romana Gerychova, Petr Janku, Ondrej Simetka, Petr Matlak, Bo Jacobsson, Marian Kacerovsky.

Project administration: Marian Kacerovsky.

Resources: Marian Kacerovsky.

Writing – original draft: Ivana Musilova, Marian Kacerovsky.

Writing – review & editing: Lenka Pliskova, Romana Gerychova, Petr Janku, Ondrej Simetka, Petr Matlak, Bo Jacobsson.

References

1. Waters TP, Mercer B. Preterm PROM: prediction, prevention, principles. Clin Obstet Gynecol. 2011; 54(2):307–12. https://doi.org/10.1097/GRF.0b013e318217d4d3 PMID: 21508700.

2. Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003; 101(1):178–93. PMID: 12517665.

3. Kumar D, Moore RM, Mercer BM, Mansour JM, Redline RW, Moore JJ. The physiology of fetal membrane weakening and rupture: Insights gained from the determination of physical properties revisited. Placenta. 2016; 42:59–73. https://doi.org/10.1016/j.placenta.2016.03.015 PMID: 27238715.

4. Menon R, Boldogh I, Hawkins HK, Woodson M, Polettini J, Syed TA, et al. Histological evidence of oxidative stress and premature senescence in preterm premature rupture of the human fetal membranes recapitulated in vitro. Am J Pathol. 2014; 184(6):1740–51. https://doi.org/10.1016/j.ajpath.2014.02.011 PMID: 24932021.

5. Menon R, Yu J, Basanta-Henry P, Brou L, Berga SL, Fortunato SJ, et al. Short fetal leukocyte telomere length and preterm prelabor rupture of the membranes. PLoS One. 2012; 7(2):e31136. https://doi.org/10.1371/journal.pone.0031136 PMID: 22348044.

6. Murtha AP, Menon R. Regulation of fetal membrane inflammation: a critical step in reducing adverse pregnancy outcome. Am J Obstet Gynecol. 2015; 213(4):447–8. https://doi.org/10.1016/j.ajog.2015.07.006 PMID: 26410204.

7. Johanzon M, Odesjo H, Jacobsson B, Sandberg K, Wennermo UB. Extreme preterm birth: onset of delivery and its effect on infant survival and morbidity. Obstet Gynecol. 2008; 111(1):42–50. https://doi.org/10.1097/AOG.0b013e318179bb68 PMID: 18165391.

8. Musilova I, Andrys C, Drahosova M, Soucek O, Stepan M, Bestvina T, et al. Intramniotic inflammation and umbilical cord blood interleukin-6 concentrations in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016; 30(8):900–10. https://doi.org/10.1080/14767058.2016.1197900 PMID: 27265200.

9. Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015; 213(4 Suppl):S29–52. https://doi.org/10.1016/j.ajog.2015.08.040 PMID: 26428501.

10. Shim SS, Romero R, Hong JS, Park CW, Jun JK, Kim BI, et al. Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol. 2004; 191(4):1339–45. https://doi.org/10.1016/j.ajog.2004.06.085 PMID: 15507963.

11. Garite TJ, Freeman RK. Chorioamnionitis in the preterm gestation. Obstet Gynecol. 1982; 59(5):539–45. PMID: 7070724.

12. Musilova I, Bestvina T, Stranik J, Stepan M, Jacobsson B, Kacerovsky M. Transabdominal Amniocentesis Is a Feasible and Safe Procedure in Preterm Prelabor Rupture of Membranes. Fetal Diagn Ther. 2017. https://doi.org/10.1159/000457965 PMID: 28237988.

13. Hawrylshyn P, Bernstein P, Milligan JE, Soldin S, Pollard A, Papsin FR. Premature rupture of membranes: the role of C-reactive protein in the prediction of chorioamnionitis. Am J Obstet Gynecol. 1983; 147(3):240–6. PMID: 6624789.

14. Romem Y, Artal R. C-reactive protein as a predictor for chorioamnionitis in cases of premature rupture of the membranes. Am J Obstet Gynecol. 1984; 150(5 Pt 1):546–50. PMID: 6496585.

15. Ismail MA, Zinaman MJ, Lowensohn RI, Moawad AH. The significance of C-reactive protein levels in women with premature rupture of membranes. Am J Obstet Gynecol. 1985; 151(4):541–4. PMID: 3976754.

16. Edelstam G, Lowbeer C, Kral G, Gustafsson SA, Venge P. New reference values for routine blood samples and human neutrophilic lipocalin during third-trimester pregnancy. Scand J Clin Lab Invest. 2001; 61(8):589–92. PMID: 11768317.
17. Chaaban M, Jauniaux E, Nasreddine S, Jabby S, Duchateau J, Wilkin P. [The significance of C-reactive protein in the diagnosis of chorioamnionitis in cases of premature rupture of the membranes]. J Gynecol Obstet Biol Reprod (Paris). 1988; 17(8):1045–9. PMID: 3235786.

18. Berardi JC, Hulin S, Godard J, Madinier V, Delanete A, Berardi-Grassias L. [The value of C-reactive protein in the detection of chorioamnionitis in cases of premature rupture of membranes]. Rev Fr Gynecol Obstet. 1991; 86(3):229–32. PMID: 1853045.

19. Yoon BH, Jun JK, Park KH, Syn HC, Gomez R, Romero R. Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. Obstet Gynecol. 1996; 88(6):1034–40. PMID: 8942849.

20. Pfleffer KA, Reinsberg J, Rahmun A, Schmolling J, Krebs D. Clinical application of maternal serum cytokine determination in premature rupture of membranes—interleukin-6, an early predictor of neonatal infection? Acta Obstet Gynecol Scand. 1999; 78(9):774–8. PMID: 10535339.

21. Sereepapong W, Limpongsanurak S, Triratanachai S, Wannakrairot P, Charurucks N, Kraladsiri P. The role of maternal serum C-reactive protein and white blood cell count in the prediction of chorioamnionitis in women with premature rupture of membranes. J Med Assoc Thai. 2001; 84 Suppl 1:S360–6. PMID: 11529358.

22. Bankowska EM, Leibschan J, Pawlowska A. [Usefulness of determination of granulocyte elastase plasma level, c-reactive protein and white blood cell count in prediction in intrauterine infection in pregnant women after PROM]. Ginekol Pol. 2003; 74(10):1037–43. PMID: 14669391.

23. Kidokoro K, Furuhashi M, Kuno N, Ishikawa K. Amniotic fluid neutrophil elastase and lactate dehydrogenase: association with histologic chorioamnionitis. Acta Obstet Gynecol Scand. 2006; 85(6):669–74. https://doi.org/10.1080/0144361060060064432 PMID: 16752257.

24. Torbe A. Maternal plasma procalcitonin concentrations in pregnancy complicated by preterm premature rupture of membranes. Mediators Inflamm. 2007; 2007:35782. https://doi.org/10.1155/2007/35782 PMID: 17710246.

25. Kacerovsky M, Musilova I, Jacobsson B, Drahosova M, Hornychova H, Janku P, et al. Cervical fluid IL-6 and IL-8 levels in pregnancies complicated by preterm prelabour rupture of membranes. J Matern Fetal Neonatal Med. 2015; 28(2):134–40. https://doi.org/10.3109/14767058.2014.908179 PMID: 24670234.

26. Kacerovsky M, Musilova I, Hornychova H, Kutova R, Pliskova L, Kostal M, et al. Bedside assessment of amniotic fluid interleukin-6 in preterm prelabour rupture of membranes. Am J Obstet Gynecol. 2014; 211(4):385 e1–9. https://doi.org/10.1016/j.ajog.2014.03.069 PMID: 24705131.

27. Kacerovsky M, Musilova I, Jacobsson B, Drahosova M, Hornychova H, Janku P, et al. Vaginal fluid IL-6 and IL-8 levels in pregnancies complicated by preterm prelabour membrane ruptures. J Matern Fetal Neonatal Med. 2015; 28(4):392–8. https://doi.org/10.3109/14767058.2014.917625 PMID: 24754733.

28. Kacerovsky M, Musilova I, Andrys C, Drahosova M, Hornychova H, Rezac A, et al. Oligohydramnios in women with preterm prelabour rupture of membranes and adverse pregnancy and neonatal outcomes. PLoS One. 2014; 9(8):e105882. https://doi.org/10.1371/journal.pone.0105882 PMID: 25171293.

29. Kacerovsky M, Pliskova L, Menon R, Kutova R, Musilova I, Maly J, et al. Microbial load of umbilical cord blood Ureaplasma species and Mycoplasma hominis in preterm prelabour rupture of membranes. J Matern Fetal Neonatal Med. 2014; 27(16):1627–32. https://doi.org/10.3109/14767058.2014.887068 PMID: 24450299.

30. Kacerovsky M, Tothova L, Menon R, Vilkova B, Musilova I, Hornychova H, et al. Amniotic fluid markers of oxidative stress in pregnancies complicated by preterm prelabour rupture of membranes. J Matern Fetal Neonatal Med. 2014; 1–10. https://doi.org/10.3109/14767058.2014.951628 PMID: 25162654.

31. Vajrychova M, Kacerovsky M, Tambor V, Hornychova H, Lenco J. Microbial invasion and histological chorioamnionitis upregulate neutrophil-gelatinase associated lipocalin in preterm prelabour rupture of membranes. J Matern Fetal Neonatal Med. 2016; 29(1):12–21. https://doi.org/10.3109/14767058.2014.991305 PMID: 25424376.

32. Musilova I, Andrys C, Drahosova M, Soucek O, Pliskova L, Jacobsson B, et al. Cervical fluid interleukin 6 and intra-amniotic complications of preterm prelabour rupture of membranes. J Matern Fetal Neonatal Med. 2017; 1–29. https://doi.org/10.1080/14767058.2017.1297792 PMID: 28277919.

33. Kacerovsky M, Musilova I, Stepan M, Andrys C, Drahosova M, Jacobsson B. Detection of intraamniotic inflammation in fresh and processed amniotic fluid samples with the interleukin-6 point of care test. Am J Obstet Gynecol. 2015; 213(3):435–6. https://doi.org/10.1016/j.ajog.2015.05.039 PMID: 26003057.

34. Musilova I, Kutova R, Pliskova L, Stepan M, Menon R, Jacobsson B, et al. Intraamniotic Inflammation in Women with Preterm Prelabour Rupture of Membranes. PLoS One. 2015; 10(7):e0133929. https://doi.org/10.1371/journal.pone.0133929 PMID: 26208287.
Fetal Neonatal Med. 2016; 29(12):1900–10. https://doi.org/10.3109/14767058.2015.1074997 PMID: 26305407.

36. Musilova I, Andrys C, Drahosova M, Hornychova H, Jacobsson B, Menon R, et al. Amniotic fluid prostaglandin E2 in pregnancies complicated by preterm prelabor rupture of the membranes. J Matern Fetal Neonatal Med. 2016; 29(18):2915–23. https://doi.org/10.3109/14767058.2015.1112372 PMID: 26512976.

37. Stepan M, Cobo T, Musilova I, Hornychova H, Jacobsson B, Kacerovsky M. Maternal Serum C-Reactive Protein in Women with Preterm Prelabor Rupture of Membranes. PLoS One. 2016; 11(3): e0150217. https://doi.org/10.1371/journal.pone.0150217 PMID: 26942752.

38. Musilova I, Andrys C, Drahosova M, Soucek O, Kutova R, Pliskova L, et al. Amniotic fluid calreticulin in pregnancies complicated by the preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016; 29(24):3921–9. https://doi.org/10.3109/14767058.2016.1154940 PMID: 26953684.

39. Musilova I, Bestvina T, Hudeckova M, Michalec I, Cobo T, Jacobsson B, et al. Vaginal fluid IL-6 concentrations as a point-of-care test is of value in women with preterm PROM. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2016.07.005 PMID: 27403846.

40. Musilova I, Andrys C, Drahosova M, Soucek O, Pliskova L, Stepan M, et al. Amniotic fluid cathepsin-G in pregnancies complicated by the preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2017; 30(17):2097–104. https://doi.org/10.1080/14767058.2016.1237499 PMID: 27651029.

41. Musilova I, Andrys C, Drahosova M, Soucek O, Pliskova L, Stepan M, et al. Amniotic fluid clusterin in pregnancies complicated by the preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2017; 30(21):2529–37. https://doi.org/10.1080/14767058.2016.1255192 PMID: 27806672.

42. Andrys C, Musilova I, Drahosova M, Soucek O, Pliskova L, Jacobsson B, et al. Cervical fluid calreticulin and cathepsin-G in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2017;1:1–8. https://doi.org/10.1080/14767058.2017.1288209 PMID: 28152632.

43. Kacerovsky M, Radochova V, Musilova I, Stepan M, Slezak R, Andrys C, et al. Levels of multiple proteins in gingival crevicular fluid and intra-amniotic complications in women with preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2017;1:1–9. https://doi.org/10.1080/14767058.2017.1347626 PMID: 28651466.

44. Kacerovsky M, Musilova I, Bestvina T, Stepan M, Cobo T, Jacobsson B. Preterm Prelabor Rupture of Membranes between 34 and 37 Weeks: A Point-of-Care Test of Vaginal Fluid Interleukin-6 Concentrations for a Noninvasive Detection of Intra-Amniotic Inflammation. Fetal Diagn Ther. 2017. https://doi.org/10.1159/000477617 PMID: 28796999.

45. Musilova I, Kacerovsky M, Stepan M, Bestvina T, Pliskova L, Zednikova B, et al. Maternal serum C-reactive protein concentration and intra-amniotic inflammation in women with preterm prelabor rupture of membranes. PLoS One. 2017;in press.

46. Musilova I, Andrys C, Drahosova M, Soucek O, Pliskova L, Stepan M, et al. Amniotic fluid cathepsin-G in pregnancies complicated by the preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016;1:1–8. https://doi.org/10.1080/14767058.2016.1237499 PMID: 27651029.

47. Kacerovsky M, Pliskova L, Bolehovska R, Musilova I, Hornychova H, Tambor V, et al. The microbial load with genital mycoplasmas correlates with the degree of histologic chorioamnionitis in preterm PROM. Am J Obstet Gynecol. 2011; 205(3):213 e1–7. https://doi.org/10.1016/j.ajog.2011.04.028 PMID: 21663889.

48. Fouhy F, Deane J, Rea MC, O’Sullivan O, Ross RP, O’Callaghan G, et al. The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations. PloS one. 2015; 10(3):e0119355. https://doi.org/10.1371/journal.pone.0119355 PMID: 25748176.

49. Greisen K, Loeffelholz M, Purohit A, Leong D. PCR primers and probes for the 16S rRNA gene of most species of pathogenic bacteria, including bacteria found in cerebrospinal fluid. Journal of clinical microbiology. 1994; 32(2):335–51. PMID: 7512093.

50. Chaemsathong P, Romero R, Korzeniewski SJ, Martinez-Varea A, Dong Z, Yoon BH, et al. A rapid interleukin-6 bedside test for the identification of intra-amniotic inflammation in preterm labor with intact membranes. J Matern Fetal Neonatal Med. 2016; 29(3):349–59. https://doi.org/10.3109/14767058.2015.1006620 PMID: 25758618.

51. Chaemsathong P, Romero R, Korzeniewski SJ, Martinez-Varea A, Dong Z, Yoon BH, et al. A point of care test for interleukin-6 in amniotic fluid in preterm prelabor rupture of membranes: a step toward the early treatment of acute intra-amniotic inflammation/infection. J Matern Fetal Neonatal Med. 2016; 29(3):360–7. https://doi.org/10.3109/14767058.2015.1006621 PMID: 25758620.

52. DiGiulio DB, Romero R, Kusnacovic JP, Gomez R, Kim CJ, Seok KS, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol. 2010; 64(1):38–57. https://doi.org/10.1111/j.1600-0897.2010.00830.x PMID: 20331587.
53. Cobo T, Tsiartas P, Kacerovsky M, Holst RM, Hougaard DM, Skogstrand K, et al. Maternal inflammatory response to microbial invasion of the amniotic cavity: analyses of multiple proteins in the maternal serum. Acta Obstet Gynecol Scand. 2013; 92(1):61–8. https://doi.org/10.1111/aogs.12028 PMID: 23057959.

54. Oh KJ, Lee KA, Sohn YK, Park CW, Hong JS, Romero R, et al. Intraamniotic infection with genital mycoplasmas exhibits a more intense inflammatory response than intraamniotic infection with other microorganisms in patients with preterm premature rupture of membranes. Am J Obstet Gynecol. 2010; 203(3):211 e1–8. https://doi.org/10.1016/j.ajog.2010.03.035 PMID: 20678747.

55. Kacerovsky M, Celec P, Vlkova B, Skogstrand K, Hougaard DM, Cobo T, et al. Amniotic fluid protein profiles of intraamniotic inflammatory response to Ureaplasma spp. and other bacteria. PLoS One. 2013; 8(3):e60399. https://doi.org/10.1371/journal.pone.0060399 PMID: 23555967.

56. Rodriguez-Trujillo A, Cobo T, Vives I, Bosch J, Kacerovsky M, Posadas DE, et al. Gestational age is more important for short-term neonatal outcome than microbial invasion of the amniotic cavity or intra-amniotic inflammation in preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 2016; 95(8):926–33. https://doi.org/10.1111/aogs.12905 PMID: 27061307.

57. Jacobsson B, Aaltonen R, Rantakokko-Jalava K, Morken NH, Alanen A. Quantification of Ureaplasma urealyticum DNA in the amniotic fluid from patients in PTL and pPROM and its relation to inflammatory cytokine levels. Acta Obstet Gynecol Scand. 2009; 88(1):63–70. https://doi.org/10.1080/00016340802572646 PMID: 19031281.

58. Kasper DC, Mechtler TP, Reischer GH, Witt A, Langgartner M, Pollak A, et al. The bacterial load of Ureaplasma parvum in amniotic fluid is correlated with an increased intrauterine inflammatory response. Diagn Microbiol Infect Dis. 2010; 67(2):117–21. https://doi.org/10.1016/j.diagmicrobio.2009.12.023 PMID: 20207094.

59. Popowski T, Goffinet F, Batteux F, Maillard F, Kayem G. [Prediction of maternalfetal infection in preterm premature rupture of membranes: serum maternal markers]. Gynecol Obstet Fertil. 2011; 39(5):302–8. https://doi.org/10.1016/j.gyobfe.2010.11.006 PMID: 21515086.

60. Ferrazzi E, Muggiasca ML, Fabbri E, Fontana P, Castoldi F, Lista G, et al. Assessment of fetal inflammatory syndrome by "classical" markers in the management of preterm labor: a possible lesson from metabolomics and system biology. J Matern Fetal Neonatal Med. 2012; 25(Suppl 5):54–61. https://doi.org/10.3109/14767058.2012.716984 PMID: 23025770.

61. Romero R, Miranda J, Chaemsaiithong P, Chaiworapongs S, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2015; 28(12):1394–409. https://doi.org/10.3109/14767058.2014.958463 PMID: 25190175.

62. Higuchi T, Omata F, Tsuchihashi K, Higashioka K, Okada S. Current cigarette smoking is a reversible cause of elevated white blood cell count: Cross-sectional and longitudinal studies. Prev Med Rep. 2016; 4:417–22. https://doi.org/10.1016/j.pmedr.2016.08.009 PMID: 27583199.

63. Smith MR, Kinmonth AL, Luben RN, Bingham S, Day NE, Wareham NJ, et al. Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. Atherosclerosis. 2003; 169(2):331–7. PMID: 12921886.